4. Lesions should be PET positive if observed in a typical FDG-avid lymphoma or the lesion was PET positive before therapy, unless the lesion is too small to be d etected with current PET systems (< 1.5 cm in its long axis by CT). Revised Protocol No.: 04 Date: 31-May-2019 191 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Measurable extranodal disease should be assessed in a manner similar to that for nodal disease. For these assessments, the spleen is considered nodal disease. Disease that is only assessable by physical examination (eg, pleural effusions, bone lesions) will be recorded as present or absent only, unless, while an abnormality is still noted by imaging studies or physical examination, it is found to be histologically negative. In clinical trials where PET is unavailable to the vast majority of participants, or where PET is not deemed necessary or appropriate for use (eg, a trial in patients with mucosa-associated lymphoid tissue lymphoma), response should be a ssessed as a bove, but only using CT scans. However, residual masses should not be assigned CRu status but should be considered a PR. Reference: Cheson BD, Pfisner B, Juweid ME, et al.